HPLC Verified
Research Grade
COA Published
Retatrutide 10mg
Retatrutide
CAS: 2381609-35-2
Retatrutide 10mg — triple GLP-1/GIP/Glucagon receptor agonist starter vial. Phase 2 data: −28.7% body weight at 48 weeks. Ideal for protocol initiation.
Price
$149.99
25 in stock
HPLC verified · third-party tested · research use only
Specifications
Triple-Agonist: GLP-1R + GIPR + GcgR
Retatrutide activates three receptors simultaneously — GLP-1R, GIPR, and GcgR. GLP-1R activation drives hypothalamic appetite suppression and delayed gastric emptying. GIPR engagement improves insulin sensitivity and enhances adipocyte lipid metabolism. GcgR (glucagon receptor) activation is the differentiating mechanism: it drives hepatic beta-oxidation (direct fat burning at the liver level) and brown adipose thermogenesis — raising resting energy expenditure independent of caloric intake. This triple mechanism produced Phase 2 data of −28.7% body weight at 48 weeks, the highest fat loss result ever recorded for any GLP compound. The 10mg starter vial provides sufficient supply to begin a dose escalation protocol.
Phase 2: −28.7% Body Weight at 48 Weeks
Retatrutide's defining clinical data: −28.7% body weight at 8mg/week over 48 weeks in Phase 2 trials. The weight loss trajectory had not plateaued at trial end, suggesting continued loss with extended protocols. This exceeds tirzepatide's best Phase 3 result (−20.9%) and semaglutide's best (−14.9%).
GcgR — Active Thermogenesis
The glucagon receptor (GcgR) is Retatrutide's differentiating mechanism. Unlike GLP-1R/GIPR which primarily suppress appetite, GcgR activation drives hepatic fat oxidation and brown adipose thermogenesis — the body burns fat directly at rest, independent of food intake. This active energy expenditure mechanism does not exist in tirzepatide or semaglutide.
Starter Vial for Protocol Initiation
The 10mg vial provides approximately 5 weeks of supply at the 2mg/week initiation dose, or sufficient material to begin a structured dose escalation protocol. Ideal for initiating research before committing to a larger supply.
Frequently Asked Questions
How long does a 10mg Retatrutide vial last?
At 2mg/week (initiation dose), 10mg covers 5 weeks. At 4mg/week, approximately 2.5 weeks. For a complete Phase 2 dose escalation cycle (2→4→8mg/week), the 15mg vial provides better supply continuity.
What is the dose escalation protocol for Retatrutide?
Phase 2 used three escalation steps: 2mg/week (weeks 1–4) → 4mg/week (weeks 5–8) → 8mg/week (week 9 onwards). This gradual escalation minimizes GI side effects during adaptation. BPC-157 should be run concurrently throughout to support gut health.
Why does Retatrutide outperform tirzepatide?
Tirzepatide is a dual agonist (GLP-1R + GIPR). Retatrutide adds glucagon receptor (GcgR) activation, which drives hepatic beta-oxidation and brown adipose thermogenesis — active fat burning mechanisms absent in tirzepatide. This third receptor is the mechanistic basis for Retatrutide's superior Phase 2 data.
Related Products
Semaglutide 3mg
Semaglutide
GLP-1 receptor agonist. 99.1% purity. Starter 3mg vial suited to initial dose-titration research; STEP-1 trial recorded −14.9% mean body weight at 68 weeks.
$49.99
CAS 910463-68-2
Semaglutide 6mg
Semaglutide
GLP-1 receptor agonist. 99.1% purity. Mid-range 6mg vial supports two-vial titration schedules; STEP-1 Phase 3 mean weight reduction −14.9% over 68 weeks.
$79.99
CAS 910463-68-2
Retatrutide 10mg
$149.99